Research Use Only / Third-Party Analytical Testing / Per-Batch Documentation / Materials Shipped from the USA
Search Account 0 Cart
CJC-1295 research material
Vial · Research materialHelio®
Helio / Materials / Growth Hormone
Growth Hormone Research

CJC-1295

CJC-1295 is a synthetic 29-amino-acid analog of growth hormone-releasing hormone (GHRH), based on the biologically active GHRH(1-29) fragment. The peptide incorporates four amino-acid substitutions (positions 2, 8, 15 and 27) engineered to increase resistance to enzymatic degradation, most notably cleavage by dipeptidyl peptidase-IV (DPP-IV). This substituted backbone is the same core sequence marketed in research contexts as "Modified GRF (1-29)." In laboratory model systems it is studied as a tool for probing GHRH-receptor signaling and pulsatile growth-hormone release from the anterior pituitary.

Two forms circulate in research use. The "No DAC" form (Mod GRF 1-29) is the unconjugated peptide with a short plasma half-life, used to model discrete, transient GHRH pulses. The "With DAC" form appends a Drug Affinity Complex (DAC) moiety that binds serum albumin, substantially extending circulating half-life and enabling investigation of sustained GHRH-receptor exposure. The identity data listed here correspond to the No DAC (Mod GRF 1-29) backbone; the DAC form carries an additional lysine-linked maleimidopropionic acid conjugate and a correspondingly higher molecular weight. All material is supplied for laboratory research only.

Identification
  • MaterialCJC-1295
  • Research AreaGrowth Hormone
  • PresentationVial
  • Available SizesNo DAC 5mg · With DAC 5mg
  • CAS Number863288-34-0
  • Molecular FormulaC152H252N44O42
  • Molecular Weight3367.9 g/mol
  • TypeSynthetic peptide (GHRH analog)
  • Receptor / TargetGrowth hormone-releasing hormone receptor (GHRH-R)
  • PubChem CID56841945 →
Amino Acid Sequence

Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2

Analytical Data
  • Purity (HPLC)≥99%
  • Identity (MS)Confirmed to specification
  • TestingAccredited (ISO 17025) third-party laboratory
  • CertificateView COA · Lot 26140001 →
From$59.95

Research use only — not for human or animal consumption. Per-batch documentation is provided with the material.

Key Characteristics
Molecular FormulaC152H252N44O42 (No DAC / Mod GRF 1-29)
Molecular Weight3367.9 g/mol (No DAC / Mod GRF 1-29)
CAS Number863288-34-0 (No DAC / Mod GRF 1-29)
PubChem CID56841945
Structure29-amino-acid GHRH(1-29) analog, amidated C-terminus
Receptor / TargetGHRH receptor (GHRH-R)
FormLyophilized powder (vial)
SolubilitySoluble in water and bacteriostatic water
StorageLyophilized: -20 C to -80 C, protected from light; short-term 4 C acceptable
StabilityLyophilized powder stable for extended periods frozen; reconstituted solution is less stable and should be kept refrigerated
Research Context
GHRH-receptor pharmacologyUsed as a receptor-selective probe to characterize GHRH-R binding, activation and downstream cAMP signaling in pituitary and heterologous cell systems.
Growth-hormone secretion dynamicsInvestigated as a tool for modeling pulsatile versus sustained GH release, particularly the contrast between the short-acting No DAC form and the long-acting DAC form.
Peptide stability engineeringServes as a reference example for studying how targeted amino-acid substitutions confer DPP-IV resistance and extend peptide half-life.
Endocrine-axis modelingApplied in research on the hypothalamic-pituitary GH axis and its interaction with downstream IGF-1 signaling.
Analytical method developmentUsed as a well-characterized reference peptide for HPLC and mass-spectrometry assay validation.
Research Findings

Published research on the CJC-1295 backbone has focused on the pharmacokinetic consequences of DPP-IV-resistant substitutions and albumin conjugation. Studies of the DAC-conjugated form report markedly prolonged circulating half-life relative to native GHRH, with sustained elevation of GH and IGF-1 in animal and early clinical model systems, whereas the unconjugated Mod GRF (1-29) form is characterized by rapid clearance and short, discrete secretory responses.

Comparative work in the GHRH-analog class has examined how conjugation strategy influences the amplitude and pattern of GH pulses, making CJC-1295 a frequently cited experimental system for distinguishing sustained-exposure from pulsatile GHRH-receptor stimulation.

History

CJC-1295 was developed in the early 2000s by ConjuChem Biotechnologies as part of a program applying Drug Affinity Complex technology to peptide hormones, extending GHRH(1-29) half-life by covalent conjugation to circulating albumin. The unconjugated substituted backbone (Modified GRF 1-29) subsequently became a widely used short-acting research counterpart, and both forms remain common reference tools in growth-hormone-axis studies.

References
  1. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
  2. Jette L, et al. hGRF1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058.
  3. Alba M, et al. Once-daily administration of CJC-1295, a long-acting GHRH analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294.

View compound profile on NIH PubChem →

Cited literature refers to laboratory and preclinical research. CJC-1295 is supplied strictly for research use only and is not intended to diagnose, treat, cure, or prevent any disease.

Why researchers choose Helio
99%+ PurityHPLC-verified every batch
Accredited TestingIndependent ISO 17025 laboratory
Per-Batch COADocumentation tied to your lot
Made in the USADiscreet, protected shipping
Related

More in Growth Hormone

View area →